These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
    Author: Togo Y, Shimatani K, Hanasaki T, Yo T, Nakanishi Y, Nagasawa S, Hashimoto T, Shiraishi Y, Taoka R, Suzuki T, Go S, Higuchi Y, Kanematsu A, Nojima M, Tsuchihashi K, Makino Y, Shimizu Y, Kanamaru S, Kono Y, Matsumoto K, Utsunomiya N, Ito N, Kawakita M, Yamamoto S.
    Journal: Hinyokika Kiyo; 2014 May; 60(5):209-14. PubMed ID: 24894855.
    Abstract:
    We prospectively investigated the safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) in 24 patients (22 males, 2 females ; age range 39-86 years, median 64 years) with metastatic renal cell carcinoma (RCC). During the observation period (3-62 weeks, median 21 weeks), thrombocytopenia was seen in 13 (54.2%), leukopenia in 11 (45.8%), hand-foot syndrome in 5 (20.8%), hypertension in 4 (16.7%), and hypothyroidism in 3 (12.5%) patients, while grade 3 or higher adverse events were found in 4 (16.7%), 1 (4.2%), 1 (4.2%), 2 (8.3%), and 0 patients, respectively. Of the 21 patients evaluable for response, 5 (23. 8%) showed partial response, 8 (38.1%) stable disease, and 8 (38.1%) progressive disease. This new modified regimen may lead to a reduction in adverse events for treatment of patients with metastatic RCC as a substitute for the standard dosing regimen of sunitinib.
    [Abstract] [Full Text] [Related] [New Search]